$55.1 Million is the total value of Ponoi II Management, LLC's 4 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NGM | NGM Biopharmaceuticals Inc | $23,004,000 | -15.7% | 1,298,908 | 0.0% | 41.78% | +3.3% | |
| RVMD | Revolution Medicines Inc | $17,242,000 | -8.5% | 685,011 | 0.0% | 31.32% | +12.2% | |
| NRIX | Sell | Nurix Therapeutics Inc | $9,470,000 | -43.7% | 327,123 | -41.7% | 17.20% | -31.0% |
| RAPT | RAPT Therapeutics Inc | $5,341,000 | +18.3% | 145,401 | 0.0% | 9.70% | +45.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NGM Biopharmaceuticals Inc | 8 | Q3 2022 | 45.2% |
| Revolution Medicines Inc | 8 | Q3 2022 | 38.8% |
| Nurix Therapeutics Inc | 8 | Q3 2022 | 24.9% |
| RAPT Therapeutics Inc | 8 | Q3 2022 | 9.7% |
| Constellation Pharmaceuticals Inc. | 3 | Q2 2021 | 43.1% |
View Ponoi II Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-08 |
| 4 | 2023-11-17 |
| 4 | 2023-02-01 |
| 4 | 2023-01-25 |
| 4 | 2023-01-23 |
| 4 | 2023-01-17 |
| 4 | 2023-01-12 |
| 4 | 2022-12-14 |
| 4 | 2022-11-23 |
| 13F-HR | 2022-11-14 |
View Ponoi II Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.